CO2017011535A2 - Composiciones de ácido obeticólico y métodos de uso - Google Patents

Composiciones de ácido obeticólico y métodos de uso

Info

Publication number
CO2017011535A2
CO2017011535A2 CONC2017/0011535A CO2017011535A CO2017011535A2 CO 2017011535 A2 CO2017011535 A2 CO 2017011535A2 CO 2017011535 A CO2017011535 A CO 2017011535A CO 2017011535 A2 CO2017011535 A2 CO 2017011535A2
Authority
CO
Colombia
Prior art keywords
methods
compositions
obetolic
acid
obetolic acid
Prior art date
Application number
CONC2017/0011535A
Other languages
English (en)
Inventor
Richard G Lancaster
Kay K Olmstead
Masashi Kagihiro
Ikuko Taoka
Mitsuhiro Matono
Mark Pruzanski
David Shapiro
Roya Hooshmand-Rad
Richard Pencek
Cathi Sciacca
Lise Eliot
Jeffrey Edwards
Leigh A Macconell
Tonya K Marmon
Original Assignee
Intercept Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57198868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017011535(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd filed Critical Intercept Pharmaceuticals Inc
Publication of CO2017011535A2 publication Critical patent/CO2017011535A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Abstract

RESUMEN La divulgación se refiere a formulaciones de ácido obeticólico con estabilidad, disolución y/o solubilidad mejoradas, a métodos para preparar las mismas para su uso y a métodos para tratar diversas enfermedades y afecciones.
CONC2017/0011535A 2015-04-27 2017-11-10 Composiciones de ácido obeticólico y métodos de uso CO2017011535A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562153040P 2015-04-27 2015-04-27
US201662317933P 2016-04-04 2016-04-04
PCT/US2016/029369 WO2016176208A1 (en) 2015-04-27 2016-04-26 Compositions of obeticholic acid and methods of use

Publications (1)

Publication Number Publication Date
CO2017011535A2 true CO2017011535A2 (es) 2018-01-31

Family

ID=57198868

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0011535A CO2017011535A2 (es) 2015-04-27 2017-11-10 Composiciones de ácido obeticólico y métodos de uso

Country Status (25)

Country Link
US (8) US10052337B2 (es)
EP (2) EP3288958A4 (es)
JP (2) JP6941057B2 (es)
KR (1) KR20170140325A (es)
CN (1) CN107531742A (es)
AU (2) AU2016255045B2 (es)
BR (1) BR112017023161A2 (es)
CA (1) CA2983609A1 (es)
CL (1) CL2017002727A1 (es)
CO (1) CO2017011535A2 (es)
CR (1) CR20170492A (es)
EA (1) EA201792354A1 (es)
EC (1) ECSP17078433A (es)
IL (2) IL255269B (es)
MA (1) MA41999A (es)
MX (1) MX2017013805A (es)
NI (1) NI201700128A (es)
PE (1) PE20180690A1 (es)
PH (1) PH12017501956A1 (es)
SG (2) SG10202003110PA (es)
SV (1) SV2017005555A (es)
TN (1) TN2017000452A1 (es)
TW (1) TWI723017B (es)
WO (1) WO2016176208A1 (es)
ZA (1) ZA201707981B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
AU2015267148B2 (en) 2014-05-28 2021-07-29 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
EP3207123A1 (en) 2014-10-17 2017-08-23 Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
US11331273B2 (en) 2016-03-31 2022-05-17 Intercept Pharmaceuticals, Inc. Film-coated tablet having high chemical stability of active ingredient
JP6968821B2 (ja) * 2016-04-13 2021-11-17 インターセプト ファーマシューティカルズ， インコーポレイテッド 癌を治療する方法
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
EP3478283A4 (en) * 2016-06-29 2020-07-22 Menlo Therapeutics Inc. USE OF NEUROKININ-1 ANTAGONISTS FOR TREATING VARIOUS PRURIGINAL DISORDERS
NZ753051A (en) * 2016-11-04 2023-03-31 Children’S Hospital Medical Center Liver organoid compositions and methods of making and using same
CN108072729A (zh) * 2016-11-18 2018-05-25 华北制药集团新药研究开发有限责任公司 一种测定奥贝胆酸片溶出度的方法
SG10202105768WA (en) 2016-12-05 2021-06-29 Childrens Hospital Med Ct Colonic organoids and methods of making and using same
CN108614038B (zh) * 2016-12-13 2022-05-17 亚宝药业集团股份有限公司 一种测定奥贝胆酸原料药有关物质的方法
CN106645497A (zh) * 2017-01-03 2017-05-10 山东省药学科学院 一种奥贝胆酸及其制剂中有关物质的检测方法
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
EP3658150A4 (en) 2017-07-24 2021-03-31 Intercept Pharmaceuticals, Inc. Isotopically labeled gallic acid derivatives
WO2019106043A1 (en) * 2017-11-29 2019-06-06 Hexal Ag Pharmaceutical composition comprising obeticholic acid
CN108572251B (zh) * 2018-05-31 2020-01-17 中国科学院昆明动物研究所 肝硬化早期小分子标志物及其应用
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
MX2021005316A (es) * 2018-11-08 2021-09-10 Intercept Pharmaceuticals Inc Métodos de uso del ácido obeticólico.
CN109432431B (zh) * 2018-12-14 2020-06-30 中国药科大学 一种含有sumo抑制剂的组合物及应用
CN109655571B (zh) * 2019-01-08 2021-07-13 丽珠集团新北江制药股份有限公司 一种奥贝胆酸的高效液相色谱分析方法
CN109620812B (zh) * 2019-01-16 2023-07-21 浙江华海药业股份有限公司 一种奥贝胆酸组合物的制备方法
JP2022527762A (ja) * 2019-03-26 2022-06-06 インターセプト ファーマシューティカルズ， インコーポレイテッド オベチコール酸を用いた肝疾患の診断および処置の方法
WO2020198576A1 (en) * 2019-03-28 2020-10-01 The Board Of Trustees Of The University Of Illinois Methods of modulating regulatory t cells
CN111690731B (zh) * 2020-05-22 2021-09-28 河南大学 Fxr激动剂在治疗肝性脑病中的应用
CN111812264B (zh) * 2020-07-09 2021-06-15 苏州旭辉检测有限公司 一种去氧胆酸类化合物的生物样品分析方法
WO2022051321A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a fxr agonist
WO2022076683A1 (en) * 2020-10-07 2022-04-14 Intercept Pharmaceuticals, Inc. Methods of treating coronaviral infection with obeticholic acid
CN113143950B (zh) * 2021-05-17 2023-04-18 河北医科大学第二医院 一种治疗肝病的药物组合物及其应用
WO2023147141A1 (en) * 2022-01-28 2023-08-03 Intercept Pharmaceuticals, Inc. Combination therapy
WO2023181077A1 (en) * 2022-03-24 2023-09-28 Zenvision Pharma Llp Stable liquid composition comprising obeticholic acid or salts thereof
WO2024043842A1 (en) * 2022-08-22 2024-02-29 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
ZA876640B (en) * 1986-09-26 1988-03-08 Warner-Lambert Company Treated lipid regulator
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
USRE48286E1 (en) 2001-03-12 2020-10-27 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
TWI239247B (en) 2001-06-14 2005-09-11 Otsuka Pharma Co Ltd Pharmaceutical composition
US6933380B2 (en) 2001-10-19 2005-08-23 Yung-Zip Chemical Ind. Co., Ltd. Excipients containing low residual solvent and method for producing the same
AU2003248786A1 (en) * 2002-07-03 2004-01-23 Esperion Therapeutics, Inc. Compositions comprising panthetine for the treatment of dyslipidemia
US20050101505A1 (en) * 2003-11-06 2005-05-12 Daniel Wood Liquid laundry detergent composition having improved color-care properties
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
JP2009500163A (ja) * 2005-07-07 2009-01-08 ナノセラピューティクス・インコーポレイテッド 粉末を製粉および調製する方法及びそれにより得られる組成物
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
JP2012520866A (ja) * 2009-03-17 2012-09-10 アプタリス・ファーマ・カナダ・インコーポレイテッド 高用量のウルソデオキシコール酸で非アルコール性脂肪性肝炎を治療する方法
US20120160944A1 (en) * 2009-04-24 2012-06-28 Aaron Dodd Method for the production of commercial nanoparticle and micro particle powders
KR20130076818A (ko) 2010-04-20 2013-07-08 시플라 리미티드 약학 조성물
CA3047776C (en) * 2012-06-19 2022-10-18 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
WO2014142364A2 (en) 2013-03-15 2014-09-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
PT3360881T (pt) 2013-05-14 2021-02-19 Intercept Pharmaceuticals Inc Derivados de 11-hidroxilo substituídos em 6 de ácidos biliares e conjugados de aminoácidos dos mesmos como moduladores do recetor farnesoide x
CA2923090C (en) * 2013-09-11 2018-08-21 Poxel Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
CN105801653B (zh) 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso

Also Published As

Publication number Publication date
EP3288958A4 (en) 2018-09-26
MA41999A (fr) 2018-03-07
AU2016255045A1 (en) 2017-11-09
EA201792354A1 (ru) 2018-03-30
US10751349B2 (en) 2020-08-25
EP3288958A1 (en) 2018-03-07
EP3971199A1 (en) 2022-03-23
IL255269A (en) 2018-02-28
US20200171053A1 (en) 2020-06-04
ECSP17078433A (es) 2018-02-28
US20200046736A1 (en) 2020-02-13
JP2021183651A (ja) 2021-12-02
TWI723017B (zh) 2021-04-01
US20200054650A1 (en) 2020-02-20
MX2017013805A (es) 2018-09-06
US10646499B2 (en) 2020-05-12
IL294575A (en) 2022-09-01
KR20170140325A (ko) 2017-12-20
BR112017023161A2 (pt) 2018-07-24
CA2983609A1 (en) 2016-11-03
PE20180690A1 (es) 2018-04-23
JP6941057B2 (ja) 2021-09-29
NI201700128A (es) 2018-04-11
TW201703773A (zh) 2017-02-01
TN2017000452A1 (en) 2019-04-12
AU2016255045B2 (en) 2020-04-16
SV2017005555A (es) 2019-01-18
US20170035784A1 (en) 2017-02-09
US10052337B2 (en) 2018-08-21
US20190076446A1 (en) 2019-03-14
SG11201708606VA (en) 2017-11-29
US20220133745A1 (en) 2022-05-05
US20200046735A1 (en) 2020-02-13
JP2018514534A (ja) 2018-06-07
WO2016176208A1 (en) 2016-11-03
AU2020205315A1 (en) 2020-08-06
CL2017002727A1 (es) 2018-04-27
IL255269B (en) 2022-08-01
CR20170492A (es) 2018-05-15
CN107531742A (zh) 2018-01-02
SG10202003110PA (en) 2020-05-28
ZA201707981B (en) 2019-03-27
US10758549B2 (en) 2020-09-01
US20190255071A1 (en) 2019-08-22
PH12017501956A1 (en) 2018-03-26

Similar Documents

Publication Publication Date Title
CO2017011535A2 (es) Composiciones de ácido obeticólico y métodos de uso
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
SV2018005610A (es) Derivados de oxopiridina sustituidos
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
EA201691582A1 (ru) Новые фармацевтические препараты
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
CR20170345A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CL2020000946A1 (es) Métodos y composiciones para la producción de trifosfato de nucleosido y ácido ribonucleico
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
BR112016020181A2 (pt) Composições de ácido lipoico éster colina e métodos de uso.
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CL2019002729A1 (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
CO2019008110A2 (es) Activador de nrf2
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
CL2017000663A1 (es) Uso de compuestos heterocíclicos fluoroalquenil sulfano para repeler moluscos